Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Shahin Lockman, Sean S. Brummel, Lauren Ziemba, Lynda Stranix‐Chibanda, Katie McCarthy, Anne Coletti, Patrick Jean‐Philippe, Ben Johnston, Chelsea Krotje, Lee Fairlie, Risa M. Hoffman, Paul E. Sax, Sikhulile Moyo, Nahida Chakhtoura, Jeffrey S. A. Stringer, Gaerolwe Masheto, Violet Korutaro, Haseena Cassim, Blandina T. Mmbaga, Esaú João, Sherika Hanley, Lynette Purdue, Lewis B. Holmes, Jeremiah D. Momper, Roger Shapiro, Navdeep Thoofer, James F. Rooney, Lisa M. Frenkel, K. Rivet Amico, Lameck Chinula, Judith S. Currier, Brookie M. Best, Cheryl Blanchette, Renee Browning, Yao Cheng, Andee Fox, Nagawa Jaliaah, Kevin Knowles, Mark Mirochnick, William Murtaugh, Emmanuel Patras, Mauricio Pinilla, Jean van Wyk, Frances Whalen
Topics & Concepts
EmtricitabineTenofovir alafenamideMedicineDolutegravirEfavirenzPregnancyInternal medicineObstetricsViral loadVirologyHuman immunodeficiency virus (HIV)Antiretroviral therapyBiologyGeneticsHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment